AIMS: Longitudinal percentage change of eight HIV-1 gag-pol mRNA cellular reservoirs from HIV-infected subjects on antiretroviral therapy was ascertained by simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI). MATERIALS #ENTITYSTARTX00026; METHODS: Serial peripheral blood mononuclear cells were taken from three subjects with treatment success, limited response and viral breakthrough plasma viral load (PVL) profiles. SUSHI was carried out on monocytes, macrophages, CD4(+) cells and naive, memory and activated T-cell reservoirs followed with broad light scatter flow cytometry. RESULTS: All gag-pol(+) reservoirs declined in the treatment success patient and similar to PVL. Only some gag-pol(+) reservoirs responded similarly to PVL for the limited treatment patient, and most gag-pol(+) reservoirs increased 16 weeks prior to PVL breakthrough in the viral breakthrough patient. CONCLUSION: SUSHI measures changes in a wide range of gag-pol(+) reservoirs in response to antiretroviral therapy.
AIMS: Longitudinal percentage change of eight HIV-1gag-pol mRNA cellular reservoirs from HIV-infected subjects on antiretroviral therapy was ascertained by simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI). MATERIALS #ENTITYSTARTX00026; METHODS: Serial peripheral blood mononuclear cells were taken from three subjects with treatment success, limited response and viral breakthrough plasma viral load (PVL) profiles. SUSHI was carried out on monocytes, macrophages, CD4(+) cells and naive, memory and activated T-cell reservoirs followed with broad light scatter flow cytometry. RESULTS: All gag-pol(+) reservoirs declined in the treatment success patient and similar to PVL. Only some gag-pol(+) reservoirs responded similarly to PVL for the limited treatment patient, and most gag-pol(+) reservoirs increased 16 weeks prior to PVL breakthrough in the viral breakthrough patient. CONCLUSION: SUSHI measures changes in a wide range of gag-pol(+) reservoirs in response to antiretroviral therapy.
Authors: D A Eckstein; M L Penn; Y D Korin; D D Scripture-Adams; J A Zack; J F Kreisberg; M Roederer; M P Sherman; P S Chin; M A Goldsmith Journal: Immunity Date: 2001-10 Impact factor: 31.745
Authors: Bernd Kupfer; Bertfried Matz; Martin P Däumer; Fabienne Roden; Jürgen K Rockstroh; Nazifa Qurishi; Ulrich Spengler; Rolf Kaiser Journal: J Med Virol Date: 2007-10 Impact factor: 2.327
Authors: Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey Journal: J Virol Date: 2002-01 Impact factor: 5.103
Authors: B K Patterson; H Behbahani; W J Kabat; Y Sullivan; M R O'Gorman; A Landay; Z Flener; N Khan; R Yogev; J Andersson Journal: J Clin Invest Date: 2001-02 Impact factor: 14.808
Authors: Tae-Wook Chun; J Shawn Justement; Richard A Lempicki; Jun Yang; Glynn Dennis; Claire W Hallahan; Christina Sanford; Punita Pandya; Shuying Liu; Mary McLaughlin; Linda A Ehler; Susan Moir; Anthony S Fauci Journal: Proc Natl Acad Sci U S A Date: 2003-01-27 Impact factor: 11.205
Authors: Fedde Groot; Toni M M van Capel; Joost Schuitemaker; Ben Berkhout; Esther C de Jong Journal: Retrovirology Date: 2006-08-17 Impact factor: 4.602
Authors: Simon Swingler; Beda Brichacek; Jean-Marc Jacque; Catherine Ulich; Jin Zhou; Mario Stevenson Journal: Nature Date: 2003-07-10 Impact factor: 69.504
Authors: Antoinette C van der Kuyl; Margreet Bakker; Suzanne Jurriaans; Nicole K T Back; Alexander O Pasternak; Marion Cornelissen; Ben Berkhout Journal: Retrovirology Date: 2013-08-28 Impact factor: 4.602
Authors: K C Jambo; D H Banda; A M Kankwatira; N Sukumar; T J Allain; R S Heyderman; D G Russell; H C Mwandumba Journal: Mucosal Immunol Date: 2014-01-29 Impact factor: 7.313